Natixis Intellia Therapeutics, Inc. Transaction History

Natixis

  • $17.6 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$23.82 - $32.8 $4,501 - $6,199
-189 Reduced 8.46%
2,045 $56,000
Q4 2023

Feb 13, 2024
SELL
$23.16 - $32.34 $22,395 - $31,272
-967 Reduced 30.21%
2,234 $68,000
Q3 2023

Nov 14, 2023
BUY
$31.62 - $45.78 $101,215 - $146,541
3,201 New
3,201 $101,000
Q1 2023

May 12, 2023
SELL
$33.3 - $44.82 $4,861 - $6,543
-146 Reduced 3.83%
3,668 $136,000
Q4 2022

Feb 24, 2023
BUY
$33.21 - $62.69 $126,662 - $239,099
3,814 New
3,814 $133,000
Q3 2022

Nov 14, 2022
SELL
$53.92 - $71.7 $10,676 - $14,196
-198 Reduced 4.54%
4,163 $238,000
Q2 2022

Aug 12, 2022
SELL
$38.49 - $76.21 $26,943 - $53,346
-700 Reduced 13.83%
4,361 $222,000
Q1 2022

May 13, 2022
SELL
$58.27 - $118.99 $27,853 - $56,877
-478 Reduced 8.63%
5,061 $368,000
Q4 2021

Feb 14, 2022
SELL
$100.76 - $138.36 $58,843 - $80,802
-584 Reduced 9.54%
5,539 $655,000
Q3 2021

Nov 12, 2021
SELL
$132.37 - $176.78 $5.81 Million - $7.76 Million
-43,885 Reduced 87.76%
6,123 $821,000
Q2 2021

Aug 13, 2021
SELL
$60.88 - $161.91 $12,845 - $34,163
-211 Reduced 0.42%
50,008 $8.1 Million
Q1 2021

May 14, 2021
BUY
$46.59 - $83.68 $1.85 Million - $3.32 Million
39,623 Added 373.94%
50,219 $4.03 Million
Q4 2020

Feb 12, 2021
BUY
$18.83 - $63.53 $199,522 - $673,163
10,596 New
10,596 $576,000

Others Institutions Holding NTLA

# of Institutions
313
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $929M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email